CDK4 and breast cancer: Furthermore, the downregulation of the endogenous CDK2 inhibitor proteins p21CIP1 and p27KIP1 leads to the increased activity of cyclin E-CDK2 complexes and has been shown to occur in CDK4/6 inhibitor-resistant BC cells [93].